1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Drugs In Development, 2022, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 3, 1, 4 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 1, 1, 1 and 1 molecules, respectively.
Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rotavirus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rotavirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rotavirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rotavirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rotavirus Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Rotavirus Infections - Overview
- Rotavirus Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Rotavirus Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Rotavirus Infections - Companies Involved in Therapeutics Development
- Aridis Pharmaceuticals Inc
- Beijing Minhai Biotechnology Co Ltd
- Bharat Biotech Ltd
- Blue Water Vaccines Inc
- Chain Biotechnology Ltd
- Chongqing Zhifei Biological Products Co Ltd
- ConserV Bioscience Ltd
- Curevac NV
- GSK plc
- Hilleman Laboratories Pvt Ltd
- IGY Immune Technologies & Life Sciences Inc
- Inventprise LLC
- Medicago Inc
- Micron Biomedical Inc
- Serum Institute of India Pvt Ltd
- SK Bioscience Ltd
- Symvivo Inc
- Wuhan Institute of Biological Products Co Ltd
- Rotavirus Infections - Drug Profiles
- Product Description
- Mechanism Of Action
- BWV-301 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IGY-106 - Drug Profile
- Product Description
- Mechanism Of Action
- poliomyelitis vaccine + rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Rotavac-5C - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rotavirus (pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- rotavirus (virus like particle) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine 1 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rotavirus [serotypes G1, G2, G3, G4, P1(8)] (pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- RV-3BB - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RV-625 - Drug Profile
- Product Description
- Mechanism Of Action
- Rotavirus Infections - Dormant Projects
- Rotavirus Infections - Product Development Milestones
- Featured News & Press Releases
- Mar 22, 2022: Blue Water Vaccines announces publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility
- Mar 04, 2021: GSK makes landmark pricing agreement for rotavirus vaccine, Rotarix, for use with children living in humanitarian crises
- Jun 03, 2019: Rotavirus vaccine (Rotarix): patient group direction (PGD) template
- Jan 24, 2018: India-made rotavirus vaccine achieves World Health Organization prequalification
- Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus
- Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate
- Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus
- Apr 26, 2012: GSK’s Rotarix To Be Introduced In Ghana
- Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan
- May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Rotavirus Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Rotavirus Infections - Pipeline by Aridis Pharmaceuticals Inc, 2022
- Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
- Rotavirus Infections - Pipeline by Bharat Biotech Ltd, 2022
- Rotavirus Infections - Pipeline by Blue Water Vaccines Inc, 2022
- Rotavirus Infections - Pipeline by Chain Biotechnology Ltd, 2022
- Rotavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
- Rotavirus Infections - Pipeline by ConserV Bioscience Ltd, 2022
- Rotavirus Infections - Pipeline by Curevac NV, 2022
- Rotavirus Infections - Pipeline by GSK plc, 2022
- Rotavirus Infections - Pipeline by Hilleman Laboratories Pvt Ltd, 2022
- Rotavirus Infections - Pipeline by IGY Immune Technologies & Life Sciences Inc, 2022
- Rotavirus Infections - Pipeline by Inventprise LLC, 2022
- Rotavirus Infections - Pipeline by Medicago Inc, 2022
- Rotavirus Infections - Pipeline by Micron Biomedical Inc, 2022
- Rotavirus Infections - Pipeline by Serum Institute of India Pvt Ltd, 2022
- Rotavirus Infections - Pipeline by SK Bioscience Ltd, 2022
- Rotavirus Infections - Pipeline by Symvivo Inc, 2022
- Rotavirus Infections - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022
- Rotavirus Infections - Dormant Projects, 2022
- Number of Products under Development for Rotavirus Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aridis Pharmaceuticals Inc
- Beijing Minhai Biotechnology Co Ltd
- Bharat Biotech Ltd
- Blue Water Vaccines Inc
- Chain Biotechnology Ltd
- Chongqing Zhifei Biological Products Co Ltd
- ConserV Bioscience Ltd
- Curevac NV
- GSK plc
- Hilleman Laboratories Pvt Ltd
- IGY Immune Technologies & Life Sciences Inc
- Inventprise LLC
- Medicago Inc
- Micron Biomedical Inc
- Serum Institute of India Pvt Ltd
- SK Bioscience Ltd
- Symvivo Inc
- Wuhan Institute of Biological Products Co Ltd
